Avelumab and Merkel Cell Carcinoma: Examining Biological Plausibility
From General Health Education to Occupational Exposure Concerns
For decades, the general health and science information landscape has provided the public with foundational knowledge on disease prevention, environmental exposures, and therapeutic interventions. This legacy heritage, rooted in broad educational outreach, has empowered individuals to understand risk factors and make informed decisions about their well-being. Within this context, discussions of pharmaceutical safety and biological plausibility have remained largely abstract, focusing on population-level trends rather than specific occupational scenarios. As we pivot from this general health framework to a more targeted concern, the focus narrows to the occupational setting where exposure to therapeutic agents may carry distinct implications. In mass production environments, workers handling pharmaceutical compounds face repeated, often prolonged contact that differs markedly from patient exposure. This shift in context demands a reexamination of risk assessment: what is considered safe for a patient under medical supervision may not translate directly to an industrial worker's daily reality. The transition from general health education to occupational exposure concern thus requires acknowledging that biological plausibility must be evaluated through the lens of exposure intensity, duration, and route—factors that are magnified in production settings. This pivot underscores the need for specialized vigilance in occupational health, moving beyond general awareness to address the unique risks inherent in pharmaceutical manufacturing.
Bridging to Avelumab: Mechanism and Therapeutic Context
Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096;https://pubmed.ncbi.nlm.nih.gov/33439294). The approval was based on the JAVELIN Merkel 200 phase II trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096). Immune checkpoint inhibition has significantly improved treatment outcomes in metastatic MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381). However, approximately 50% of patients do not respond or develop immune-related adverse events (irAEs) due to mechanisms such as down-regulation of MHC complexes or induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385).
Biological Plausibility: Does Avelumab Cause Merkel Cell Carcinoma?
The biological plausibility of avelumab causing or contributing to Merkel cell carcinoma is not supported by the available evidence. Instead, avelumab is a therapeutic agent used to treat MCC, and its mechanism of action—blocking PD-L1 to enhance T-cell responses—is directed against the tumor. Approximately 80% of MCC cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385). Avelumab does not introduce a new carcinogenic pathway; rather, it modulates the immune system to attack existing cancer cells. The reported adverse effects of avelumab include immune-related events such as hypercalcaemia due to reactivation of sarcoidosis, which can be managed with corticosteroids and does not necessitate discontinuation of therapy (https://pubmed.ncbi.nlm.nih.gov/31543781). There is no evidence in the provided sources linking avelumab to the initiation or promotion of MCC.
Timeline and Causation Considerations for Affected Patients
Regarding causation-related considerations for affected patients, the timeline between avelumab exposure and documented harm must be examined. In the context of MCC treatment, avelumab is administered to patients who already have the disease. The JAVELIN Merkel 200 trial demonstrated responses in patients with chemotherapy-refractory MCC, indicating that avelumab is used after diagnosis (https://pubmed.ncbi.nlm.nih.gov/29799096). For patients who are refractory to avelumab, subsequent treatment with ipilimumab plus nivolumab has shown efficacy, with three out of five patients in a small study responding according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294). This suggests that avelumab-refractory disease does not imply causation of MCC by avelumab, but rather a lack of response to the therapy. The development of irAEs, such as hypercalcaemia from sarcoidosis reactivation, occurs during treatment and is temporally related to avelumab exposure, but these events are distinct from the causation of MCC itself (https://pubmed.ncbi.nlm.nih.gov/31543781).
Adequacy of Warnings and Risk Communication
The adequacy of warnings regarding avelumab and Merkel cell carcinoma is addressed in the prescribing information and clinical literature. Avelumab is indicated for the treatment of metastatic MCC, and its approval was based on efficacy data in this population (https://pubmed.ncbi.nlm.nih.gov/29799096). The risk of irAEs is well-documented, and management strategies, such as corticosteroid use, are established (https://pubmed.ncbi.nlm.nih.gov/31543781). However, the evidence does not suggest that avelumab causes MCC; rather, it is a treatment for the condition. Warnings appropriately focus on immune-related adverse events and the potential for lack of response, not on carcinogenicity. For affected patients, the primary causation consideration is that avelumab is used to treat an existing MCC diagnosis, and any harm from the drug is related to its immunomodulatory effects, not to inducing the cancer.
Summary of Evidence and Implications
In summary, the biological plausibility of avelumab causing Merkel cell carcinoma is not supported by the evidence. Avelumab is a PD-L1 inhibitor approved for treating metastatic MCC, and its use is based on clinical trials showing efficacy in this patient population. The timeline of exposure and harm is consistent with avelumab being administered after MCC diagnosis, and adverse events are immune-related rather than carcinogenic. Warnings adequately address the risks of irAEs, and causation considerations for patients should focus on the drug's role as a treatment, not a cause, of MCC. References https://pubmed.ncbi.nlm.nih.gov/33439294https://pubmed.ncbi.nlm.nih.gov/36450381https://pubmed.ncbi.nlm.nih.gov/29799096https://pubmed.ncbi.nlm.nih.gov/31543781https://pubmed.ncbi.nlm.nih.gov/34445385
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
Can avelumab cause Merkel cell carcinoma?
No, the available evidence does not support that avelumab causes Merkel cell carcinoma. Avelumab is a treatment for MCC, and its mechanism of action targets existing cancer cells. MCC is primarily caused by the Merkel cell polyomavirus or UV-induced mutations, not by avelumab.
What are the main risks associated with avelumab?
The main risks are immune-related adverse events (irAEs) such as hypercalcaemia from sarcoidosis reactivation, which can be managed with corticosteroids. These events are temporally related to avelumab exposure but are distinct from causing MCC.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.